Biological markers of Alzheimer's disease;Biomarcadores da doença de Alzheimer

Arquivos de Neuro-Psiquiatria

Volumn 72, Issue 3, 2014, Pages 227-231

  de Souza, Leonardo Cruz ^a,b   Sarazin, Marie ^a,c   Teixeira Junior, Antônio Lúcio ^b   Caramelli, Paulo ^b   dos Santos, Antônio Emanuel ^a   Dubois, Bruno ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c INSERM   (France)

Author keywords

Alzheimer's disease; CSF biomarkers

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN DAMAGE; CEREBROSPINAL FLUID; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; EARLY DIAGNOSIS; HIPPOCAMPAL SCLEROSIS; HUMAN; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; PATHOPHYSIOLOGY; PHENOTYPE; PRIMARY PROGRESSIVE APHASIA; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; HUMANS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84897865370     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/0004-282X20130233     Document Type: Review

References (60)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-344.
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019-1031.
3. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement 2010;6:98-103.
4. Sarazin M, Dorothee G, de Souza LC, Aucouturier P. Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle? Biol Psychiatry 2013;74:329-332.
5. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-144.
6. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-389.
7. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Medicine 2010;8:89.
8. Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006;129:3035-3041.
9. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652-656.
10. Tapiola T, Overmyer M, Lehtovirta M, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997;8:3961-3963.
11. Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009;65:927-934.
12. Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009;50:1464-1470.
13. Seppala TT, Nerg O, Koivisto AM, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012;78:1568-1575.
14. Schoonenboom NS, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012;78:47-54.
15. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010;67:949-956.
16. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008;4:38-48.
17. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-1452.
18. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64:850-855.
19. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-1562.
20. Visser PJ, Knopman DS. Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI. Neurology 2009;73:744-745.
21. Molinuevo JL, Gispert JD, Dubois B, et al. The AD-CSF-Index discriminates Alzheimer's disease patients from healthy controls: a validation study. J Alzheimers Dis 2013;36:67-77.
22. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619-627.
23. Jack CR, Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
24. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
25. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
26. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
27. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Jama 2009;302:385-393.
28. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.
29. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
30. Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009;73:1353-1358.
31. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010;74:1531-1537.
32. Koric L, Felician O, Guedj E, et al. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? Alzheimer Dis Assoc Disord 2010;24:278-283.
33. van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009;72:1056-1061.
34. Apostolova LG, Hwang KS, Andrawis JP, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010;31:1284-1303.
35. de Souza LC, Chupin M, Lamari F, et al. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol Aging 2012;33:1253-1257.
36. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci 2010;30:2088-2101.
37. Hampel H, Burger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005;62:770-773.
38. Henneman WJ, Vrenken H, Barnes J, et al. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009;73:935-940.
39. Leow AD, Yanovsky I, Parikshak N, et al. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensorbased morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009;45:645-655.
40. Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008;70:1827-1835.
41. Bibl M, Mollenhauer B, Lewczuk P, et al. Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 2011;31:37-44.
42. de Souza LC, Lamari F, Belliard S, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry 2011;82:240-246.
43. Grossman M, Farmer J, Leight S, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 2005;57:721-729.
44. Kapaki E, Paraskevas GP, Papageorgiou SG, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2008;22:47-53.
45. Warren JD, Fletcher PD, Golden HL. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol 2012;8:451-464.
46. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007;130:2636-2645.
47. Kas A, de Souza LC, Samri D, et al. Neural correlates of cognitive impairment in posterior cortical atrophy. Brain 2011;134:1464-1478.
48. Mendez MF, Joshi A, Tassniyom K, Teng E, Shapira JS. Clinicopathologic differences among patients with behavioral variant frontotemporal dementia. Neurology 2013;80:561-568.
49. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10:785-96.
50. Snowden JS, Thompson JC, Stopford CL, et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011;134:2478-2492.
51. Renner JA, Burns JM, Hou CE, McKeel DW, Jr., Storandt M, Morris JC. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology 2004;63:1175-1180.
52. Cummings J. Primary progressive aphasia and the growing role of biomarkers in neurological diagnosis. Ann Neurol 2008;64:361-364.
53. Deramecourt V, Lebert F, Debachy B, et al. Prediction of pathology in primary progressive language and speech disorders. Neurology 2010;74:42-49.
54. de Souza LC, Corlier F, Habert MO, et al. Similar amyloid-{beta} burden in posterior cortical atrophy and Alzheimer's disease. Brain 2011;134:2036-2043.
55. Kas A, Uspenskaya O, Lamari F, et al. Distinct brain perfusion pattern associated with CSF biomarkers profile in progressive aphasia J Neurol Neurosurg Psychiatry 2012;83:695-698.
56. Leyton CE, Villemagne VL, Savage S, et al. Subtypes of progressive aphasia: application of the international consensus criteria and validation using {beta}-amyloid imaging. Brain 2011;134: 3030-3043.
57. Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008;64:388-401.
58. Gorno-TempiniML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006-1014.
59. de Souza LC, Bertoux M, Funkiewiez A, et al. Frontal presentation of Alzheimer's disease: a series of patients with biological evidence by CSF biomarkers Dement Neuropsychol 2013;7:66-74.
60. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.